FDA Approves Veklury as First Treatment for COVID-19 – Renal and Urology News
The FDA approved Veklury (remdesivir; Gilead Sciences) for the treatment of COVID-19 in patients aged ≥12 years (weighing ≥40kg) requiring hospitalization.
The FDA approved Veklury (remdesivir; Gilead Sciences) for the treatment of COVID-19 in patients aged ≥12 years (weighing ≥40kg) requiring hospitalization.
Researchers conducted a systematic literature review to determine the prevalence of hypogonadism among high-risk men who underwent cancer treatment.
TempMonitor is able to provide a visual indicator when a medication has been exposed to unacceptable temperature levels.
A review of the literature explored the potential of medicinal cannabis as a treatment for depression, anxiety, and stress in patients with active cancer.
Cancer-related survival differed by cancer type.
Hypomagnesemia was one of several risk factors identified for high-grade hypertension after VSPI initiation for cancer treatment.
Women with OSA have higher median Interstitial Cystitis Symptom Index, Interstitial Cystitis Problem Index
Researchers compared the efficacy and safety of oral gepotidacin with that of nitrofurantoin in female patients with uncomplicated urinary tract infections.
Can monosodium urate crystal deposition ultrasound findings at certain joints predict future gout flares over 12 months in patients initiating urate-lowering therapy?
Researchers conducted a study to evaluate whether the incidence of proteinuria in men with prediabetes differs by HIV serostatus.
Substantial increases in CKD, dialysis, and health-related costs are projected internationally for 2022 to 2032.